ScienceVest Weekly Deal — Get a closing, diligenced private science deal to your inbox

@joaquin_beltran We typically help scientists connect with the right resources that are stage-appropriate and track their progress over time to a point where we can be helpful, typically when they are ready to raise outside funding.

@miguelrios fantastic question and something worth it's own blog post, but the short version is there are a few trends that only recently have come together to make these types of companies even more attractive for the right kind of investor than they've been historically (think Intel, Google, Genentech, Tesla, etc). These are many of the trends that apply to all startups (costs of storage, computing, etc nearing $0), but new ones that also apply to science (costs for megabase of DNA sequence, per genome, etc also approaching $0) on top of new startups that provide services that typically were reserved for big Co's (ScienceExchange being the UpWork for science talent, Genscript as the mechanical turk for research, etc). These make the path for these companies to IPO/Exit is now similar to your average tech startup (~11yr avg time to IPO), but with much better economics for a shorter hold period. One of the most recent companies that best highlight these trends recently is Stemcentrx (acquired by AbbVie for $10.2B, ~7 yrs to exit).

@amoreda We've built a sourcing and screening platform to review companies and teams from every major research institution, science-focused incubator and accelerator, research institute, among other sources in the U.S. Selection occurs through an extensive review process of both the business and science - leveraging the expertise and experience of accomplished scientists and investors that are part of our diligence advisory network.